SPIRIT study boost for Guidant's DES (drug-eluting stent) programme
This article was originally published in Clinica
Latest trial data from Guidant suggest that the firm may have a second strong drug-eluting stent (DES) in its pipeline.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.